Chemo-radiotherapy of oligometastases of colorectal cancer with pegylated liposomal mitomycin-C prodrug (PROMITIL): Mechanistic basis and preliminary clinical experience

Esther Tahover; Rachel Bar-Shalom; Eli Sapir; Raphael Pfeffer; Igor Nemirovsky; Yehonatan Turner; Maya Gips; Patricia Ohana; Benjamin W. Corn; Andrew Z. Wang; Alberto A. Gabizon

doi:10.3389/fonc.2018.00544

Chemo-radiotherapy of oligometastases of colorectal cancer with pegylated liposomal mitomycin-C prodrug (PROMITIL): Mechanistic basis and preliminary clinical experience

Esther Tahover, Rachel Bar-Shalom, Eli Sapir, Raphael Pfeffer, Igor Nemirovsky, Yehonatan Turner, Maya Gips, Patricia Ohana, Benjamin W. Corn, Andrew Z. Wang, Alberto A. Gabizon

Research output: Contribution to journal › Article › peer-review

11 Scopus citations

Abstract

Hypo-fractionated radiotherapy and stereotactic body radiotherapy are viable options for treatment of oligometastases. A prodrug of mitomycin-C is under clinical testing as a pegylated liposomal formulation (Promitil) with an improved safety profile over mitomycin-C. Promitil was offered to two patients with oligometastases from colorectal cancer as radiosensitizer. Each derived durable clinical benefit from Promitil administered immediately prior to and following irradiation. Transient toxicity to normal tissues of moderate to severe degree was observed. Promitil appears to have potential clinical value in this setting.

Original language	English (US)
Article number	544
Journal	Frontiers in Oncology
Volume	8
Issue number	NOV
DOIs	https://doi.org/10.3389/fonc.2018.00544
State	Published - 2018
Externally published	Yes

Keywords

Colorectal cancer
Liposomes
Mitomycin-C
Oligometastases
Prodrug
Radiosensitizer
Radiotherapy

ASJC Scopus subject areas

Oncology
Cancer Research

Access to Document

10.3389/fonc.2018.00544

Cite this

Tahover, E., Bar-Shalom, R., Sapir, E., Pfeffer, R., Nemirovsky, I., Turner, Y., Gips, M., Ohana, P., Corn, B. W., Wang, A. Z., & Gabizon, A. A. (2018). Chemo-radiotherapy of oligometastases of colorectal cancer with pegylated liposomal mitomycin-C prodrug (PROMITIL): Mechanistic basis and preliminary clinical experience. Frontiers in Oncology, 8(NOV), Article 544. https://doi.org/10.3389/fonc.2018.00544

Tahover, E, Bar-Shalom, R, Sapir, E, Pfeffer, R, Nemirovsky, I, Turner, Y, Gips, M, Ohana, P, Corn, BW, Wang, AZ & Gabizon, AA 2018, 'Chemo-radiotherapy of oligometastases of colorectal cancer with pegylated liposomal mitomycin-C prodrug (PROMITIL): Mechanistic basis and preliminary clinical experience', Frontiers in Oncology, vol. 8, no. NOV, 544. https://doi.org/10.3389/fonc.2018.00544

@article{7d59ec0080164975bfd31e30f83b0f6d,

title = "Chemo-radiotherapy of oligometastases of colorectal cancer with pegylated liposomal mitomycin-C prodrug (PROMITIL): Mechanistic basis and preliminary clinical experience",

abstract = "Hypo-fractionated radiotherapy and stereotactic body radiotherapy are viable options for treatment of oligometastases. A prodrug of mitomycin-C is under clinical testing as a pegylated liposomal formulation (Promitil) with an improved safety profile over mitomycin-C. Promitil was offered to two patients with oligometastases from colorectal cancer as radiosensitizer. Each derived durable clinical benefit from Promitil administered immediately prior to and following irradiation. Transient toxicity to normal tissues of moderate to severe degree was observed. Promitil appears to have potential clinical value in this setting.",

keywords = "Colorectal cancer, Liposomes, Mitomycin-C, Oligometastases, Prodrug, Radiosensitizer, Radiotherapy",

author = "Esther Tahover and Rachel Bar-Shalom and Eli Sapir and Raphael Pfeffer and Igor Nemirovsky and Yehonatan Turner and Maya Gips and Patricia Ohana and Corn, {Benjamin W.} and Wang, {Andrew Z.} and Gabizon, {Alberto A.}",

note = "Publisher Copyright: Copyright {\textcopyright} 2018 Tahover, Bar-Shalom, Sapir, Pfeffer, Nemirovsky, Turner, Gips, Ohana, Corn, Wang and Gabizon.",

year = "2018",

doi = "10.3389/fonc.2018.00544",

language = "English (US)",

volume = "8",

journal = "Frontiers in Oncology",

issn = "2234-943X",

publisher = "Frontiers Media S. A.",

number = "NOV",

}

TY - JOUR

T1 - Chemo-radiotherapy of oligometastases of colorectal cancer with pegylated liposomal mitomycin-C prodrug (PROMITIL)

T2 - Mechanistic basis and preliminary clinical experience

AU - Tahover, Esther

AU - Bar-Shalom, Rachel

AU - Sapir, Eli

AU - Pfeffer, Raphael

AU - Nemirovsky, Igor

AU - Turner, Yehonatan

AU - Gips, Maya

AU - Ohana, Patricia

AU - Corn, Benjamin W.

AU - Wang, Andrew Z.

AU - Gabizon, Alberto A.

PY - 2018

Y1 - 2018

N2 - Hypo-fractionated radiotherapy and stereotactic body radiotherapy are viable options for treatment of oligometastases. A prodrug of mitomycin-C is under clinical testing as a pegylated liposomal formulation (Promitil) with an improved safety profile over mitomycin-C. Promitil was offered to two patients with oligometastases from colorectal cancer as radiosensitizer. Each derived durable clinical benefit from Promitil administered immediately prior to and following irradiation. Transient toxicity to normal tissues of moderate to severe degree was observed. Promitil appears to have potential clinical value in this setting.

AB - Hypo-fractionated radiotherapy and stereotactic body radiotherapy are viable options for treatment of oligometastases. A prodrug of mitomycin-C is under clinical testing as a pegylated liposomal formulation (Promitil) with an improved safety profile over mitomycin-C. Promitil was offered to two patients with oligometastases from colorectal cancer as radiosensitizer. Each derived durable clinical benefit from Promitil administered immediately prior to and following irradiation. Transient toxicity to normal tissues of moderate to severe degree was observed. Promitil appears to have potential clinical value in this setting.

KW - Colorectal cancer

KW - Liposomes

KW - Mitomycin-C

KW - Oligometastases

KW - Prodrug

KW - Radiosensitizer

KW - Radiotherapy

UR - http://www.scopus.com/inward/record.url?scp=85063288966&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85063288966&partnerID=8YFLogxK

U2 - 10.3389/fonc.2018.00544

DO - 10.3389/fonc.2018.00544

M3 - Article

C2 - 30534533

AN - SCOPUS:85063288966

SN - 2234-943X

VL - 8

JO - Frontiers in Oncology

JF - Frontiers in Oncology

IS - NOV

M1 - 544

ER -

Chemo-radiotherapy of oligometastases of colorectal cancer with pegylated liposomal mitomycin-C prodrug (PROMITIL): Mechanistic basis and preliminary clinical experience

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this